OncoCyte Corporation (OCX)
NASDAQ: OCX · Real-Time Price · USD
3.240
-0.130 (-3.86%)
May 27, 2025, 3:03 PM - Market open
OncoCyte Revenue
OncoCyte had revenue of $2.14M in the quarter ending March 31, 2025, with 1,114.77% growth. This brings the company's revenue in the last twelve months to $3.84M, up 178.08% year-over-year. In the year 2024, OncoCyte had annual revenue of $1.88M with 25.15% growth.
Revenue (ttm)
$3.84M
Revenue Growth
+178.08%
P/S Ratio
15.28
Revenue / Employee
$78,429
Employees
49
Market Cap
92.66M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1.88M | 378.00K | 25.15% |
Dec 31, 2023 | 1.50M | 545.00K | 56.89% |
Dec 31, 2022 | 958.00K | -1.24M | -56.41% |
Dec 31, 2021 | 2.20M | 982.00K | 80.76% |
Dec 31, 2020 | 1.22M | - | - |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
OCX News
- 7 days ago - Medicare Boosts Reimbursement for Oncocyte's Flagship Technology - GlobeNewsWire
- 14 days ago - OncoCyte Corporation (OCX) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 14 days ago - Oncocyte Reports Q1 2025 Results and Business Progress - GlobeNewsWire
- 19 days ago - Oncocyte to Release First Quarter 2025 Results on May 12, 2025 - GlobeNewsWire
- 27 days ago - Oncocyte Provides Positive Update on Clinical Trial Progress - GlobeNewsWire
- 4 weeks ago - Oncocyte's Proprietary Assay Demonstrates Long-Term Clinical Validity - GlobeNewsWire
- 2 months ago - OncoCyte Corporation (OCX) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025 - GlobeNewsWire